According to a drug trial that was presented at the American College of Rheumatology in San Francisco indicates that methotrexate, when used in combination with tocilizumab, resulted in remission in 47% of the patients. This compares to only 8% for patients on methotrexate alone. [...]
|
|||||||
|
A recent review of treatments for Psoriatic arthritis (PsA) found that the benefit of different therapies depended how widespread the disease was. Psoriatic arthritis is the second most common cause of joint inflammation. It involves the skin and joints, but may also affect fingers and toes, eyes and the spine. The effect on the [...] Biogen Idec Inc. announced on October 9th that it was discontinuing development of its investigational rheumatoid arthritis (RA) drug baminercept after if failed to meet Phase II study endpoints. [...] In the last post I described the basics about infectious arthritis. It can be caused by bacteria, fungus or virus. The warning signs to look for differ based on the type of germ that caused the joint infection. Something to keep in mind is that people with chronic health conditions tend to be more [...] Rheumatoid arthritis (RA) is a known risk factor in hardening of the arteries which in turn leads to strokes and heart attacks on average 10 years earlier than people without RA. Previous studies that have shown that treating rheumatoid arthritis with disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate, may reduce the risk of heart [...] |
  
|
||||||
|
Copyright © 2012 Current Arthritis News and Research - All Rights Reserved
|
|||||||
